A non-government resource for the Medicare community
Powered by Q1Group LLC
A non-government Medicare community resource
  • Menu
  • Home
  • Contact
  • MAPD
  • PDP
  • 2024
  • 2025
  • FAQs
  • Articles
  • Search
  • Contact
  • 2024
  • 2025
  • FAQs
  • Articles
  • Latest Medicare News
  • Search

April 2024 Medicare Drug List Updates: Forty-seven (47) medications added to the 2024 Medicare Part D Drug plan formularies.

Category: Monthly Formulary changes
Published: Apr, 29 2024 08:04:15


The April 2024 Medicare Part D prescription drug plan formulary (drug list) data is now online and included in our Formulary Browser and Q1Rx Drug Finder.

The April formulary updates include the addition of 67 new National Drug Codes (NDCs), representing 47 different prescription drugs, many with multiple strengths.

The formulary updates impact both stand-alone Medicare Part D plans (PDPs) and Medicare Advantage plans with drug coverage (MAPDs).


Highlights of the April 2024 Formulary updates include eight (8) newly-introduced brand-name drugs

The April drug data updates include nineteen (19) new brand-name drugs, eight (8) of which are newly introduced brand-name drugs, some with multiple strengths. These drugs include:
  • AGAMREE®,
  • IWILFIN®,
  • PENBRAYA®,
  • VOQUEZNA®,
  • WAINUA®,
  • XALKORI ®,
  • ZILBRYSQ®, and
  • ZITUVIO®.

The April 2024 Formulary updates include ten (10) newly-added generic drugs

The April Medicare Part D drug data also includes twenty-eight (28) new generic medications, ten (10) of which are newly-introduced generic drugs.  These new generic drugs include:
  • BROMFENAC SODIUM [Prolensa®],
  • CLOBETASOL [Temovate Scalp®],
  • DAPAGLIFLOZIN [Farxiga®],
  • DAPAGLIFLOZIN-METFORMIN [Xigduo XR®],
  • FLUOROMETHOLONE [FML®],
  • FLURAZEPAM [Dalmane®],
  • GABAPENTIN [Gralise®],
  • INSULIN GLARGINE [Toujeo SoloStar®],
  • RISPERIDONE [Risperdal Consta®], and
  • RISPERIDONE [Rykindo®].
Please note that these new generic and brand-name drugs are not available on all Medicare Part D or Medicare Advantage drug plans - and you can review the chart to see the (often limited) number of plan formularies that now include these drugs.


Reminders about Medicare prescription drug plan formulary changes
  1. Medicare Part D plans (PDPs and MAPDs) can change their formulary or drug list during the year and may drop one of your formulary medication mid-year for specific Medicare-allowable reasons (such as a new generic drug is available), but there are steps you can take if your medication is no longer covered by your prescription drug plan.

  2. In most cases, your Medicare Part D plan will notify you if the plan drops a medication you are currently using.

Good to know: What is the NDC?

The NDC or National Drug Code is used to uniquely identify a particular drug, manufacturer, strength, and packaging combination. The NDC is often shown on your prescription bottle as an 11-digit code (see the charts below) or could be formatted as 00000-0000-00 where the first set of numbers identifies the drug manufacturer, the second set of number identifies the product and strength, and the third set of numbers identifies the packaging.  You can read more here: Q1FAQ.com/155


Summary of April 2024 NDC changes

There are many reasons for NDCs to be added to the Medicare Part D program, a summary for all 67 new April 2024 NDCs is as follows:

Reason for NDC Addition Occurrences
New Delivery Form 3
New Delivery Form and Strength 5
New Drug 17
New Drug and Delivery Form 2
New Drug and Strength 28
New Manufacturer 1
New Manufacturer and Delivery Form 1
New Manufacturer and Strength 7
New Manufacturer, Strength and Delivery Form 1
New Strength 2
Grand Total 67

The following chart details the 67 new manufacturer / drug-strength / packaging combinations (NDCs) that were added to one or more Medicare Part D formularies in the most recent updates -- as you will notices, some drugs are only covered by a few Medicare plans.

You can click on the Drug Name below to go to our Q1Medicare.com Drug Finder (Q1Rx.com) and see the details of how this drug is covered by all Medicare Part D plans (PDPs) in Florida (our example state).  You can then change the state in our search form for details of drug coverage in your service area.


NDC Drug Name Number of
PDP Formularies*
Number of
MAPD Formularies*
Notes
69616026438 AGAMREE 40 MG/ML ORAL SUSPENSION 0 3 New Drug
00168026415 ALCLOMETASONE DIPR 0.05% OINTMENT [Aclovate] 42 340 New Manufacturer and Delivery Form
53746024830 ALOSETRON HCL 0.5 MG TABLET [Lotronex] 54 369 New Drug and Strength
53746024930 ALOSETRON HCL 1 MG TABLET [Lotronex] 54 369 New Drug and Strength
73308040760 AMCINONIDE 0.1% OINTMENT [Cyclocort] 2 47 New Drug
69489020130 AMZEEQ 4% FOAM 0 1 New Drug
68308075130 BIJUVA 0.5 MG-100 MG CAPSULE 2 22 New Manufacturer and Strength
70539040004 BINOSTO 70 MG EFFERVESCENT TABLET 0 3 New Drug
00069101415 BOSULIF 100 MG CAPSULE 52 365 New Delivery Form and Strength
00069050430 BOSULIF 50 MG CAPSULE 52 366 New Delivery Form and Strength
82260060203 BROMFENAC SODIUM 0.07% EYE DROPS [Prolensa] 25 205 New Drug
45802088996 CALCIPOTRIENE-BETAMETH DP SUSPENSION [Taclonex Scalp] 1 29 New Drug
58151007993 CARDURA XL 8 MG TABLET ER 24H 0 25 New Manufacturer and Strength
73473030660 CLINDA-TRETINOIN 1.2%-0.025% GEL [Ziana] 1 11 New Drug
00168026950 CLOBETASOL 0.05% SOLUTION [Temovate Scalp] 41 362 New Drug
16714049602 CLOTRIMAZOLE-BETAMETHASONE CREAM (G) [Lotrisone] 54 369 New Drug
66993045730 DAPAGLIFLOZIN 10 MG TABLET [Farxiga] 0 7 New Drug and Strength
66993045630 DAPAGLIFLOZIN 5 MG TABLET [Farxiga] 0 7 New Drug and Strength
66993036230 DAPAGLIFLOZIN-METFOR ER 10-1000 TABLET BP 24H [Xigduo XR] 0 6 New Drug and Strength
66993036160 DAPAGLIFLOZIN-METFOR ER 5-1000 TABLET BP 24H [Xigduo XR] 0 6 New Drug and Strength
62135043230 DISULFIRAM 500 MG TABLET [Antabuse] 54 343 New Drug
72578008707 FLUOCINONIDE 0.1% CREAM (G) [Vanos] 6 99 New Drug
60219158503 FLUOROMETHOLONE 0.1% EYE DROPS with DROPPER [FML] 48 368 New Drug
62135073630 FLURAZEPAM 15 MG CAPSULE [Dalmane] 1 28 New Drug and Strength
62135073730 FLURAZEPAM 30 MG CAPSULE [Dalmane] 1 32 New Drug and Strength
45802044102 FLUTICASONE PROP 0.05% LOTION [Cutivate] 3 51 New Delivery Form and Strength
69616029038 FYCOMPA 0.5 MG/ML ORAL SUSPENSION 54 369 New Manufacturer, Strength and Delivery Form
69616028030 FYCOMPA 10 MG TABLET 54 369 New Drug and Strength
69616028230 FYCOMPA 12 MG TABLET 54 369 New Drug and Strength
69616027230 FYCOMPA 2 MG TABLET 54 369 New Drug and Strength
69616027430 FYCOMPA 4 MG TABLET 54 369 New Drug and Strength
69616027630 FYCOMPA 6 MG TABLET 54 369 New Drug and Strength
69616027830 FYCOMPA 8 MG TABLET 54 369 New Drug and Strength
68382060816 GABAPENTIN ER 300 MG TABLET 24H [Gralise] 0 46 New Manufacturer and Strength
68382060716 GABAPENTIN ER 600 MG TABLET 24H [Neurontin] 0 46 New Manufacturer and Strength
70183024130 INPEFA 400 MG TABLET 0 16 New Strength
00955290002 INSULIN GLARGINE MAX SOLO U300 INSULN PEN [Toujeo SoloStar] 0 44 New Drug and Strength
00955390003 INSULIN GLARGINE SOLOSTAR U300 INSULN PEN [Toujeo SoloStar] 0 44 New Drug and Strength
78670015001 IWILFIN 192 MG TABLET 54 367 New Drug
10337090510 Kerydin 5% Solution with Applicator 10 ML 0 2 New Drug
58151015777 LIPITOR 40 MG TABLET 0 4 New Manufacturer and Strength
64380016001 MEGESTROL ACET 40 MG/ML ORAL SUSPENSION [Megace] 54 369 New Delivery Form
13668048750 MINOCYCLINE HCL 100 MG TABLET [Myrac] 12 184 New Strength
45802011942 MOMETASONE FUROATE 0.1% OINTMENT [Elocon] 54 369 New Delivery Form
00168008915 NYSTATIN-TRIAMCINOLONE OINTMENT [Mytrex] 30 265 New Drug and Delivery Form
00168008130 Nystatin and Triamcinolone Acetonide 30G Topical Cream 28 269 New Drug and Delivery Form
00069060001 PENBRAYA Prefilled Syringe 54 365 New Drug
00480155408 RISPERIDONE ER 12.5 MG VIAL [Risperdal Consta] 42 296 New Drug and Strength
00480123208 RISPERIDONE ER 25 MG VIAL [Rykindo] 42 296 New Drug and Strength
00480134208 RISPERIDONE ER 37.5 MG VIAL [Rykindo] 42 296 New Drug and Strength
00480145308 RISPERIDONE ER 50 MG VIAL [Rykindo] 42 296 New Drug and Strength
43386070002 SOD SUL-POTASS SUL-MAG SUL SOLN RECON [Suprep] 54 327 New Drug and Strength
16729037010 TADALAFIL 5 MG TABLET [Cialis] 1 73 New Manufacturer and Strength
70726030401 TEGLUTIK 5 MG/ML ORAL SUSPENSION [TIGLUTIK] 3 33 New Manufacturer
72888016230 TRAMADOL HCL 25 MG TABLET 1 8 New Manufacturer and Strength
81520010030 VOQUEZNA 10 MG TABLET 0 4 New Drug and Strength
81520020030 VOQUEZNA 20 MG TABLET 0 4 New Drug and Strength
00310940001 WAINUA 45 MG/0.8 ML AUTOINJECTOR 0 8 New Drug
00069150060 XALKORI 150 MG PELLET DSP CP 54 369 New Delivery Form and Strength
00069025160 XALKORI 20 MG PELLET DSP CP 54 369 New Delivery Form and Strength
00069050760 XALKORI 50 MG PELLET DSP CP 54 369 New Drug
50474099180 ZILBRYSQ 23 MG/0.574 ML SYRINGE 3 47 New Drug and Strength
50474099280 ZILBRYSQ 32.4 MG/0.81 ML SYRINGE 3 47 New Drug and Strength
70710124203 ZITUVIO 100 MG TABLET 0 2 New Drug and Strength
70710124003 ZITUVIO 25 MG TABLET 0 2 New Drug and Strength
70710124103 ZITUVIO 50 MG TABLET 0 2 New Drug and Strength
80610043060 ZORYVE 0.3% FOAM 0 5 New Delivery Form




If your brand-name drug is no longer covered by your Medicare Part D plan, you can use the 30-day notice period (if notice is provided) to:
Learn more in our article: How a mid-year formulary change can affect your Medicare Part D drug coverage.

Our online Formulary Browser and Drug Finder

You can review any Medicare plan formulary using the Q1Medicare.com Formulary Browser found at: FormularyBrowser.com or compare how any medication is covered on all Medicare plans in your Service Area using our Drug Finder found at: Q1Rx.com.








Tips & Disclaimers
  • Q1Medicare®, Q1Rx®, and Q1Group® are registered Service Marks of Q1Group LLC and may not be used in any advertising, publicity, or for commercial purposes without the express authorization of Q1Group.
  • The Medicare Advantage and Medicare Part D prescription drug plan data on our site comes directly from Medicare and is subject to change.
  • Medicare has neither reviewed nor endorsed the information on our site.
  • We provide our Q1Medicare.com site for educational purposes and strive to present unbiased and accurate information. However, Q1Medicare is not intended as a substitute for your lawyer, doctor, healthcare provider, financial advisor, or pharmacist. For more information on your Medicare coverage, please be sure to seek legal, medical, pharmaceutical, or financial advice from a licensed professional or telephone Medicare at 1-800-633-4227.
  • We are an independent education, research, and technology company. We are not affiliated with any Medicare plan, plan carrier, healthcare provider, or insurance company. We are not compensated for Medicare plan enrollments. We do not sell leads or share your personal information.
  • Benefits, formulary, pharmacy network, provider network, premium and/or co-payments/co-insurance may change on January 1 of each year. Our PDPCompare.com and MACompare.com provide highlights of annual plan benefit changes.
  • The benefit information provided is a brief summary, not a complete description of benefits. For more information contact the plan.
  • Limitations, copayments, and restrictions may apply.
  • We make every effort to show all available Medicare Part D or Medicare Advantage plans in your service area. However, since our data is provided by Medicare, it is possible that this may not be a complete listing of plans available in your service area. For a complete listing please contact 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week or consult www.medicare.gov.
    Statement required by Medicare:
    "We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options."
  • When enrolling in a Medicare Advantage plan, you must continue to pay your Medicare Part B premium.
  • Medicare beneficiaries with higher incomes may be required to pay both a Medicare Part B and Medicare Part D Income Related Monthly Adjustment Amount (IRMAA). Read more on IRMAA.
  • Medicare Advantage plans that include prescription drug coverage (MAPDs) are considered Medicare Part D plans and members with higher incomes may be subject to the Medicare Part D Income Related Monthly Adjustment Amount (IRMAA), just as members in stand-alone Part D plans. In certain situations, you can appeal IRMAA.
  • You must be enrolled in both Medicare Part A and Part B to enroll in a Medicare Advantage plan. Members may enroll in a Medicare Advantage plan only during specific times of the year. Contact the Medicare plan for more information.
  • If you are enrolled in a Medicare plan with Part D prescription drug coverage, you may be eligible for financial Extra Help to assist with the payment of your prescription drug premiums and drug purchases. To see if you qualify for Extra Help, call: 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048, 24 hours a day/ 7 days a week or consult www.medicare.gov; the Social Security Office at 1-800-772-1213 between 7 a.m. and 7 p.m., Monday through Friday. TTY users should call, 1-800-325-0778; or your state Medicaid Office.
  • Medicare evaluates plans based on a 5-Star rating system. Star Ratings are calculated each year and may change from one year to the next.
  • A Medicare Advantage Private Fee-for-Service plan (PFFS) is not a Medicare supplement plan. Providers who do not contract with the plan are not required to see you except in an emergency.
  • Disclaimer for Institutional Special Needs Plan (SNP): This plan is available to anyone with Medicare who meets the Skilled Nursing Facility (SNF) level of care and resides in a nursing home.
  • Disclaimer for Dual Eligible (Medicare/Medicaid) Special Needs Plan (SNP): This plan is available to anyone who has both Medical Assistance from the State and Medicare. Premiums, co-pays, co-insurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.
  • Disclaimer for Chronic Condition Special Needs Plan (SNP): This plan is available to anyone with Medicare who has been diagnosed with the plan specific Chronic Condition.
  • Medicare MSA Plans combine a high deductible Medicare Advantage Plan and a trust or custodial savings account (as defined and/or approved by the IRS). The plan deposits money from Medicare into the account. You can use this money to pay for your health care costs, but only Medicare-covered expenses count toward your deductible. The amount deposited is usually less than your deductible amount, so you generally have to pay out-of-pocket before your coverage begins.
  • Medicare MSA Plans do not cover prescription drugs. If you join a Medicare MSA Plan, you can also join any separate (stand-alone) Medicare Part D prescription drug plan
  • There are additional restrictions to join an MSA plan, and enrollment is generally for a full calendar year unless you meet certain exceptions. Those who disenroll during the calendar year will owe a portion of the account deposit back to the plan. Contact the plan provider for additional information.
  • Medicare beneficiaries may enroll through the CMS Medicare Online Enrollment Center located at www.medicare.gov.
  • Medicare beneficiaries can file a complaint with the Centers for Medicare & Medicaid Services by calling 1-800-MEDICARE 24 hours a day/7 days or using the medicare.gov site. Beneficiaries can appoint a representative by submitting CMS Form-1696.